Medicilon Assists Gluetacs Therapeutics' second molecular rubber pipeline line GT929 achieves dual filing and batching in China and US
On October 27, Gluetacs Therapeutics’ second Class 1 new drug, GT929 capsule, in its molecular glue degrader pipeline, was approved by the U.S. Food and Drug Administration (FDA) to enter clinical trials for the treatment of malignant hematological tumors. This pipeline has previously been approved by the National Medical Products Administration (NMPA) to conduct clinical trials on July 24, 2023, and is expected to enroll the first patient in China's Phase I clinical study at the end of 2023. This is the second product pipeline of Gluetacs Therapeutics to be approved for clinical trials in both China and the United States after GT919, which is another milestone in the globalization process of Gluetacs Therapeutics. GT919 and GT929 are experimental drugs used in Phase I clinical studies As a strategic partner of Gluetacs Therapeutics, Shanghai Medicilon Inc. (Medicilon) provided formulation research and preclinical research (including efficacy , pharmacokinetics ,...